Bio-Gene Technology Ltd. (AU:BGT)
ASX:BGT
Top Page
Bio-Gene Technology Ltd.
(Sydney:BGT)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.03
▲(65.00% Upside)
Action:ReiteratedDate:03/24/26
The score is primarily weighed down by very weak financial performance (zero revenue, persistent losses, and ongoing cash burn with shrinking equity). Technicals are mixed-to-slightly supportive (positive MACD and trading above longer-term averages), but valuation is constrained by losses (negative P/E) and no dividend yield.
Positive Factors
Regulatory progress (Flavocide)
Advancing OECD-standard toxicology work and targeting an APVMA submission in March 2027 materially reduces regulatory uncertainty over the medium term. Successful pivotal studies underpin multi-jurisdiction filings, de-risk commercial launch pathways and expand addressable markets for professional and domestic insecticide applications.
Negative Factors
Zero revenue in FY2025
Reporting zero revenue in FY2025 signals a lack of commercial sales traction. Without recurring product revenues, the company remains dependent on partnerships, grants and capital raises to fund operations, delaying the onset of sustainable margins and cash generation and elevating execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory progress (Flavocide)
Advancing OECD-standard toxicology work and targeting an APVMA submission in March 2027 materially reduces regulatory uncertainty over the medium term. Successful pivotal studies underpin multi-jurisdiction filings, de-risk commercial launch pathways and expand addressable markets for professional and domestic insecticide applications.
Read all positive factors
Bio-Gene Technology Ltd. (BGT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$9.76M
Dividend YieldN/A
Average Volume (3M)988.87K
Price to Earnings (P/E)―
Beta (1Y)-0.43
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding305,061,100
10 Day Avg. Volume246,330
30 Day Avg. Volume988,871
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.08
Price to Sales (P/S)0.00
P/FCF Ratio-1.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bio-Gene Technology Ltd. Business Overview & Revenue Model
Company Description
Bio-Gene Technology Limited, an agtech development company, engages in developing and commercializing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flav...
Bio-Gene Technology Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 18.32K | 149.23K | 445.73K | 62.61K |
| Gross Profit | -47.16K | -245.78K | -301.45K | -164.04K | 178.59K | -110.59K |
| EBITDA | -3.32M | -2.58M | -2.97M | -3.14M | -2.92M | -2.85M |
| Net Income | -1.96M | -2.58M | -2.41M | -3.10M | -2.91M | -2.40M |
Balance Sheet | ||||||
| Total Assets | 1.47M | 2.15M | 3.16M | 3.84M | 7.30M | 5.00M |
| Cash, Cash Equivalents and Short-Term Investments | 1.08M | 1.14M | 2.21M | 2.99M | 6.34M | 3.93M |
| Total Debt | 0.00 | 51.21K | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 307.71K | 522.98K | 368.45K | 613.88K | 1.03M | 754.57K |
| Stockholders Equity | 1.17M | 1.63M | 2.79M | 3.22M | 6.27M | 4.25M |
Cash Flow | ||||||
| Free Cash Flow | -1.78M | -2.54M | -2.76M | -3.28M | 36.67K | -1.83M |
| Operating Cash Flow | -1.78M | -2.54M | -2.75M | -3.28M | 43.52K | -1.83M |
| Investing Cash Flow | 0.00 | 0.00 | -5.70K | 0.00 | -6.84K | -3.03K |
| Financing Cash Flow | 2.36M | 1.47M | 1.98M | -75.00K | 4.41M | 239.88K |
Bio-Gene Technology Ltd. Technical Analysis
Positive
0.02
Price Trends
0.03
Positive
0.03
Positive
0.03
Positive
Market Momentum
<0.01
Positive
63.38
Neutral
54.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BGT, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 63.38 is Neutral, neither overbought nor oversold. The STOCH value of 54.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BGT.
Bio-Gene Technology Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$7.52M | -3.15 | -17.07% | ― | ― | 71.10% | |
48 Neutral | AU$13.12M | -1.00 | -218.76% | ― | ― | ― | |
44 Neutral | AU$9.76M | -1.25 | -140.35% | ― | ― | ― | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
40 Underperform | AU$2.17M | -4.31 | -32.19% | ― | ― | 46.43% | |
39 Underperform | AU$5.95M | -1.39 | 56.41% | ― | -99.31% | 90.20% |
* Healthcare Sector Average
AU:BGT
Bio-Gene Technology Ltd.
0.03
>-0.01
-5.88%
AU:ZLD
Zelira Therapeutics
0.50
0.04
8.70%
AU:IXC
Invex Therapeutics Ltd.
0.10
0.03
47.06%
AU:CMB
Regeneus Ltd.
0.48
0.18
57.38%
AU:1AD
AdAlta Ltd.
―
―
―
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
Bio-Gene Technology Ltd. Corporate Events
Bio-Gene advances Qcide oil production and prepares for large-scale expansion
Mar 9, 2026
Bio-Gene Technology has completed its 15th harvest and extraction of Qcide oil from its far north Queensland plantation, confirming that standardized processing continues to deliver oil meeting commercial specifications. The company’s tree i...
Bio-Gene Targets 2027 APVMA Filing as Flavocide Toxicology Program Advances
Mar 2, 2026
Bio-Gene Technology has reported solid progress in the regulatory development of its novel insecticidal active constituent, Flavocide, with a series of toxicology and metabolism studies advancing according to plan. Early toxicology data have been ...
Bio-Gene Advances Bio-Insecticide Pipeline with New Approvals, Grants and Capital Raise
Feb 23, 2026
Bio-Gene reported its financial and operational progress for the half year to 31 December 2025, highlighting steady advancement of its bio-insecticide portfolio. The company completed its 14th Qcide harvest, advanced biomass pre-treatment and extr...
Bio-Gene Advances Pivotal Flavocide Toxicity Study Toward Regulatory Approval
Feb 9, 2026
Bio-Gene Technology has commenced a pivotal extended one-generation reproductive toxicity study in rats for its novel insecticidal active ingredient, Flavocide, a core requirement for regulatory approval in Australia and other key jurisdictions. T...
Bio-Gene Names New CFO and Company Secretary to Support Commercialisation Push
Feb 1, 2026
Bio-Gene Technology Limited has appointed experienced finance executive Drew Speedy as Chief Financial Officer and Company Secretary, effective 1 February 2026, replacing outgoing CFO and Company Secretary Edmond Tern. With more than two decades i...
Bio-Gene Builds Momentum as Flavocide and Qcide Move Toward Commercial Stage
Jan 29, 2026
Bio-Gene Technology reported strong operational momentum in the December 2025 quarter as it advanced both its Flavocide and Qcide insecticide platforms from foundational RD into more mature regulatory, formulation and commercial development. The c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.